Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TTR | P02766 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | SELL | P14151 | 1/20 | 0.40 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
| ▸ | SELE | P16581 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450984 | 1.00 | ALDH1A1 (0.55) | ALDH1A1TTRALBMEN1KMT2A | |
| SCHEMBL501406 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TTRALBMEN1KMT2A | |
| SCHEMBL214163 | 0.82 | CA12 (0.52) | TTRALBMEN1KMT2ACA12 | |
| SCHEMBL509092 | 0.82 | CA12 (0.52) | ALDH1A1TTRALBMEN1KMT2A | |
| SCHEMBL1004620 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TTRALBMEN1KMT2A | |
| SCHEMBL9264989 | 0.82 | CA12 (0.52) | TTRALBMEN1KMT2ACA12 | |
| Phenol SCHEMBL28330144 | 0.79 | CA12 (0.46) | ALDH1A1TTRALBMEN1KMT2A | |
| SCHEMBL12535886 | 0.78 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2AACHEHCAR1 | |
| Orcinol SCHEMBL17085568 | 0.77 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ACA12CA2 | |
| SCHEMBL7039619 | 0.76 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2ACA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630420-A1 | INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | claimed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | claimed |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024121184-A1 | INHIBITORS OF NLRP3 | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | claimed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | claimed |
| EP-4630420-A1 | INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| CN-116283658-B | Hydrazide hydrazone HIF-2 alpha inhibitor and application thereof | 浙江大学医学院附属第一医院 | 2025-04-25 | — | — | CN | disclosed |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | MERCK SHARP & DOHME LLC (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2024218100-A1 | OXAZOLO[4,5-B]PYRAZINE AND OXAZOLO[4,5-B]PYRIDINE DERIVATIVES AS NLRP3 INHIBITORS FOR THE TREATMENT OF E.G. INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-24 | — | — | WO | disclosed |
| EP-4433459-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| US-12077506-B2 | Indane derivatives as hypoxia inducible factor-2(α) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077506-B2 | Indane derivatives as hypoxia inducible factor-2(α) inhibitors | HIF1AN, HIF1A, NFE2L2 | ALDH1A1 642/4885TTR 4745/4885ALB 4113/4885 |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | TYMP, PNP, CD4 | ALDH1A1 2371/4885TTR 2015/4885ALB 4437/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | ALDH1A1 385/4885TTR 1407/4885ALB 3317/4885 |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | ALDH1A1 2364/4885TTR 4754/4885ALB 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.